Spectral Medical Announces Second Quarter Results

Spectral Medical Inc., (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2020.

Financial Review

Revenue for the three months ended June 30, 2020 was $517,000 compared to $1,041,000 for the same three-month period last year. For the six-months ended June 30, 2020, revenue was $1,148,000 compared to $1,588,000 in the first half of 2019. The majority of the decrease is due to the timing of orders for product revenue and the non-recurring technology transfer revenue. This was mitigated by an increase in royalty revenue, and revenue from the exclusive distribution agreement with Baxter International Inc. (“Baxter”).

Operating costs for the quarter-ended June 30, 2020, were $2,466,000 compared to $2,093,000 for the corresponding period in 2019. Operating costs for the six-months ended June 30, 2020 were $6,522,000, an increase of $2,889,000 from $3,633,000 for the six-month period ended June 30, 2019. The increase is a result of the ramping up of the Company’s Phase III clinical trial, whereby costs vary depending on the timing and level of patient enrolment. In addition, there was an increase in share compensation expense, due to options being granted earlier in 2020 that had higher share option valuations compared to the share option valuation for share options issued in 2019. Salaries and benefits also increased by approximately $189,000 for the six-months ended June 30, 2020 due to the addition of the Company’s CFO, who joined in August, 2019. Furthermore,  as previously stated, the Company incurred one-time costs associated with a legacy financial advisory services agreement relating to the commercial transaction agreement completed with Baxter and the withdrawn prospectus offering in March 2020. Lastly, there was a 4% decline in the CAD/USD exchange rate in the period from March 31, 2020 to June 30, 2020, which resulted in a foreign exchange loss in the second quarter, reversing the foreign exchange gain recorded in the first quarter of 2020. The CAD/USD exchange rate was relatively consistent throughout 2019.

The Company continues to maintain a low cost operating structure for its base business operations.

For the three-months ended June 30, 2020, the Company reported a loss of $1,949,000 ($0.009 loss per share) compared to a loss of $1,052,000 ($0.005 loss per share) for the three-months ended June 30, 2019. Loss for the six-months ended June 30, 2020 was $5,374,000 ($0.024 loss per share) compared to a loss of $2,045,000 ($0.009 loss per share) for the same period last year.

The Company concluded the second quarter of 2020 with cash of $10,230,000 compared to $1,435,000 cash on hand as of December 31, 2019. This cash balance reflects the non-refundable US$5,000,000 (CA$6,629,000) upfront rights payment from Baxter, which was received in the first quarter, as well as the net proceeds of $4,397,000 received on the public offering, reduced by operating cash outflows.  Based on current operating plans, Spectral expects to have cash to fund its 2020 business plan.

The total number of common shares outstanding for the Company was 236,605,745 as at June 30, 2020.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version